KalVista Pharmaceuticals is a pharmaceutical company. Co. develops a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). Co. has an oral Factor XIIa inhibitor program which provides HAE therapeutics. Co. focuses on developing oral plasma kallikrein inhibitors for HAE, which includes its product candidates, KVD900, a potential oral on-demand therapy for HAE attacks; and KVD824, an oral product candidate for potential prophylactic treatment of HAE. Co.'s DME program is focused on the development of an intravitreally administered small molecule plasma kallikrein inhibitor, KVD001. The KALV stock yearly return is shown above.
The yearly return on the KALV stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KALV annual return calculation with any dividends reinvested as applicable (on ex-dates).
|